GBE Deficiency (GSD IV and APBD) Natural History Study

Duke University logo

Duke University

Status

Enrolling

Conditions

Adult Polyglucosan Body Disease
Glycogen Storage Disease Type IV
APBD
GSD IV
GSD4

Treatments

Other: No intervention

Study type

Observational

Funder types

Other

Identifiers

NCT02683512
Pro00060753

Details and patient eligibility

About

Collection and review of clinical information related to glycogen branching enzyme (GBE) deficiency, diagnosed as Glycogen Storage Disease Type IV (GSD IV) or Adult Polyglucosan Body Disease (APBD generated during clinic visits.

Full description

This natural history study will serve as a repository of clinical, laboratory, and biochemical information on individuals with GBE deficiency, diagnosed as either GSD IV or APBD. This information will allow a more definitive description of GBE deficiency to be developed, which will permit development of treatment strategies for this disease. Duke will be the only site where this study takes place. However, since this is a rare disorder, participants who receive care for GBE deficiency at other institutions will be included. We will collect retrospective data from patient charts on diagnosed individuals, as far back as necessary to capture the clinical course of the disorder. Prospective data collected from patient charts after enrollment will be captured as well. Participant's medical records will be continually reviewed for the duration of the study. Data will be collected from medical records and will only pertain to clinically relevant information, including, but not limited to: demographic and diagnostic information, tissue biopsy results, medical and family history, review of systems, imaging studies, results of liver, muscle, and nerve function testing, and urine and blood laboratory results.

Enrollment

200 estimated patients

Sex

All

Ages

Under 90 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

  • Diagnosis of GSD IV or APBD via:

    • Two variants in the GBE1 gene
    • Deficient GBE activity in liver, muscle, skin fibroblast or other tissue
    • One variant in GBE1 gene with evidence of disease that is pathogenic, per the clinician
  • Able to provide informed consent for self (adults) or affected individual (minor or adults with a legally authorized representative)

  • Able to provide consent for release of medical records

  • Pregnant women with a diagnosis of GSD IV or APBD will be included

  • Histology as confirmed by clinician

Trial contacts and locations

1

Loading...

Central trial contact

Rebecca L Koch, PhD, RDN; Nisha Dalal, M.S. CCC-SLP

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems